Description

Cardiogen 20mg – AEDR Bioregulator Research Peptide

Cardiogen 20mg is a synthetic tetrapeptide associated with scientific investigations into short peptide bioregulation, myocardial tissue biology and molecular interactions involving cellular proteins. Commonly identified by the amino acid sequence Ala-Glu-Asp-Arg (AEDR), Cardiogen belongs to a family of short regulatory peptides studied within the Khavinson research programme.

The Cardiogen peptide has attracted research interest because of its association with experimental cardiac tissue models and investigations into peptide interactions with histones and other molecular structures. Its scientific background includes laboratory and preclinical studies rather than established human clinical applications.

Cardiogen 20mg is intended to be evaluated as a research material. Its exact chemical identity, purity and suitability for specific experiments depend on verified manufacturer documentation and batch-specific analytical results.

What Is Cardiogen Peptide?

Cardiogen is commonly described as a synthetic tetrapeptide composed of four amino acids: alanine, glutamic acid, aspartic acid and arginine.

Its commonly reported amino acid sequence is Ala-Glu-Asp-Arg, abbreviated AEDR.

Cardiogen is associated with the Khavinson school of short peptide bioregulation, which investigated the possible interactions of small peptide sequences with biological systems.

Within this research tradition, Cardiogen has been linked to myocardial and cardiovascular tissue investigations.

However, its classification as a cardiac bioregulator is a research designation rather than proof of heart-protective or therapeutic effects.

Cardiogen 20mg Product Specifications

• Product Name: Cardiogen 20mg – Bioregulator Peptide
• Alternative Name: AEDR Peptide
• Commonly Reported Sequence: Ala-Glu-Asp-Arg
• One-Letter Amino Acid Sequence: AEDR
• Peptide Classification: Synthetic tetrapeptide
• Peptide Length: 4 amino acids
• Labelled Quantity: 20mg
• Molecular Formula: C18H31N7O9 (unmodified free peptide)
• Approximate Molecular Weight: 489.48 g/mol (unmodified free peptide)
• Research Category: Short peptide bioregulation
• Research Focus: Myocardial tissue models, peptide-protein interactions and cellular regulation
• Purity: Requires batch-specific analytical verification
• Physical Form: Confirm with manufacturer
• Storage: Follow verified manufacturer instructions
• Intended Use: Laboratory research

Understanding the Cardiogen AEDR Peptide Structure

Cardiogen consists of four amino acid residues connected through peptide bonds.

The commonly reported AEDR sequence contains the following components:

• Alanine (A): A small amino acid with a nonpolar side chain.
• Glutamic Acid (E): An amino acid with an acidic side chain that contributes to molecular charge.
• Aspartic Acid (D): Another acidic amino acid involved in protein structure and molecular interactions.
• Arginine (R): A positively charged amino acid that can participate in electrostatic interactions with biological molecules.

These amino acids form the sequence Ala-Glu-Asp-Arg, commonly written as H-Ala-Glu-Asp-Arg-OH for the unmodified free peptide.

The molecular formula C18H31N7O9 and approximate molecular weight of 489.48 g/mol apply to this unmodified peptide structure. Commercially supplied salts, counterions or modified forms may have different analytical characteristics.

Scientific Research Associated With Cardiogen

1. Myocardial Tissue Research

Cardiogen has been associated with experimental investigations involving myocardial tissue, the specialised muscular tissue that forms the walls of the heart.

Some research within the Khavinson programme has examined short peptides in organotypic tissue culture models.

Organotypic cultures preserve certain structural and cellular features of tissues, allowing researchers to investigate biological responses under controlled laboratory conditions.

Experimental observations in such models may contribute to hypotheses about tissue regulation.

However, changes observed in isolated tissue cultures cannot establish that Cardiogen improves heart function or repairs damaged cardiac muscle in living humans.

2. Cardiomyocyte and Cardiac Cell Biology

Cardiomyocytes are specialised muscle cells responsible for generating the contractions of the heart.

Research into cardiac cell biology investigates cellular organisation, protein expression, responses to injury and the regulation of tissue maintenance.

Cardiogen is associated with the broader investigation of short regulatory peptides in cardiac-related experimental systems.

Its direct effects on human cardiomyocyte function remain insufficiently characterised.

Claims that Cardiogen increases cardiac strength, restores damaged heart cells or improves cardiovascular performance are not established by reliable human clinical evidence.

3. Peptide-Histone Interaction Research

Histones are proteins that help organise DNA within the cell nucleus.

Interactions between histones and other molecules are important to the structure of chromatin, the complex formed by DNA and associated proteins.

Published laboratory research involving short peptides, including AEDR, has investigated their interactions with histone proteins.

These experiments provide a molecular research context for Cardiogen and related peptide sequences.

However, observing a peptide-histone interaction under experimental conditions does not prove that the peptide produces beneficial changes in human gene expression or tissue function.

4. Peptide-DNA and Chromatin Research

Short peptides are investigated for their potential interactions with DNA and chromatin-associated structures.

The chemical properties of amino acid side chains can influence how peptides interact with charged biological molecules.

Cardiogen contains both acidic residues and a basic arginine residue, making its molecular interactions an area of experimental interest.

Research into these interactions may help scientists explore fundamental aspects of peptide chemistry and molecular recognition.

Any proposed relationship between these laboratory observations and cardiovascular health remains speculative without appropriate biological and clinical validation.

5. Cellular Proliferation and Tissue Regulation

Cellular proliferation is the process through which cells divide and increase in number.

Researchers studying short peptide bioregulators have examined changes in cellular proliferation and tissue responses in experimental systems.

Cardiogen has been discussed in connection with organotypic tissue investigations, including myocardial-related models.

These findings should be interpreted within the limitations of the experimental methods.

In particular, an increase in cell proliferation does not automatically represent tissue repair, improved organ function or a beneficial physiological outcome.

6. Age-Related Tissue Biology

The Khavinson peptide research programme has also explored molecular and cellular changes associated with ageing.

Age-related research may examine alterations in gene expression, tissue maintenance, protein regulation and cellular responses.

Cardiogen is sometimes discussed within this wider research context because of its classification as a short peptide bioregulator.

However, there is no established human clinical evidence demonstrating that Cardiogen reverses cardiac ageing, increases lifespan or prevents age-related cardiovascular disease.

How Does Cardiogen Work?

The precise biological mechanism of Cardiogen has not been conclusively established.

Some laboratory studies associated with AEDR and related short peptides have investigated molecular interactions with histones and other cellular components.

These observations have contributed to hypotheses about peptide-mediated cellular regulation.

However, a specific, clinically validated receptor target or signalling mechanism has not been established for Cardiogen.

It should therefore not be described as a proven cardiac receptor agonist, cardiovascular repair agent or therapeutic regulator of heart function.

Cardiogen and Cardiovascular Research

Cardiovascular research investigates the structure and function of the heart and blood vessels, including cellular signalling, tissue injury and disease-related biological processes.

Cardiogen is associated with this research field through its historical classification and limited preclinical literature.

Potential research questions include the interactions of short peptides with cellular proteins and the responses of experimental myocardial tissue systems.

These research associations should not be confused with evidence that Cardiogen treats hypertension, heart failure, coronary artery disease, arrhythmias or other cardiovascular conditions.

Cardiogen is not an established cardiovascular medicine.

Cardiogen vs Vesugen: What Is the Difference?

Cardiogen and Vesugen are different synthetic peptides associated with the Khavinson bioregulator research tradition.

• Cardiogen: Commonly identified as the AEDR tetrapeptide, Ala-Glu-Asp-Arg.
• Vesugen: Commonly identified as the KED tripeptide, Lys-Glu-Asp.
• Peptide Length: Cardiogen contains four amino acids, while Vesugen contains three.
• Research Association: Cardiogen has been associated with myocardial tissue research, while Vesugen has been investigated in vascular and endothelial research contexts.

These peptides have distinct chemical structures, and findings involving one cannot automatically be applied to the other.

Cardiogen vs Other Khavinson Bioregulator Peptides

Cardiogen belongs to a wider family of short synthetic peptides investigated for their possible interactions with biological systems.

Other examples include:

• Epitalon: AEDG tetrapeptide, associated with ageing-related experimental research.
• Bronchogen: Commonly marketed as the AEDL tetrapeptide, associated with respiratory epithelial research.
• Pinealon: EDR tripeptide, associated with neuronal and cellular research.
• Ovagen: EDL tripeptide, discussed within short peptide bioregulator research.

Although these peptides share some amino acid residues, each has a distinct molecular identity.

Similarities in peptide sequence do not establish identical biological effects or therapeutic properties.

What Does Cardiogen 20mg Mean?

The 20mg designation identifies the labelled quantity of peptide material supplied.

It does not represent a recommended human dose or independently verify the peptide’s purity, molecular identity or suitability for administration.

Researchers should confirm the exact quantity, molecular form and analytical specifications using manufacturer documentation.

Cardiogen 20mg Research Quality and Product Documentation

When evaluating Cardiogen research material, important product documentation includes:

• Confirmation of the AEDR amino acid sequence
• Verification of the unmodified or modified molecular form
• Batch-specific certificate of analysis
• Peptide identity testing
• Analytical purity results
• Accurate labelled quantity
• Manufacturer and batch traceability
• Information about counterions or other formulation components
• Packaging and container specifications
• Verified storage and stability instructions
• Clearly stated research-use classification

These details are important for ensuring that research materials are accurately identified and appropriately documented.

Storage and Handling of Cardiogen Peptide

Cardiogen 20mg should be stored according to verified manufacturer instructions.

Storage conditions depend on the peptide’s physical form, formulation, packaging and available stability data.

Researchers should not assume that every Cardiogen product has identical storage requirements or shelf-life characteristics.

Laboratory handling should follow the relevant safety documentation and institutional procedures.

Cardiogen Safety and Scientific Limitations

Cardiogen remains an investigational peptide with limited preclinical evidence.

Its human pharmacokinetics, long-term safety, potential adverse effects and clinical effectiveness have not been adequately established.

Laboratory studies involving peptide-protein interactions or isolated tissue models do not demonstrate that Cardiogen prevents or treats cardiovascular disease.

Cardiogen is not an established FDA-, EMA- or MHRA-approved medicine for cardiac treatment.

This product information is intended for scientific and educational purposes only and does not provide medical advice, human dosing recommendations or administration instructions.

Frequently Asked Questions About Cardiogen 20mg

What is Cardiogen 20mg?

Cardiogen 20mg is a product listing for a synthetic tetrapeptide commonly identified as Ala-Glu-Asp-Arg (AEDR), with a labelled quantity of 20mg.

What is the Cardiogen peptide sequence?

The commonly reported sequence is Ala-Glu-Asp-Arg, abbreviated AEDR.

What is Cardiogen researched for?

Cardiogen is associated with experimental investigations into short peptide bioregulation, myocardial tissue models and peptide interactions with cellular proteins.

Is Cardiogen a cardiac bioregulator?

Cardiogen is commonly classified as a cardiac bioregulator within the Khavinson research tradition. This classification does not establish proven cardiovascular benefits.

Does Cardiogen improve heart function?

There is insufficient reliable human clinical evidence demonstrating that Cardiogen improves heart function or treats cardiovascular disease.

What is the molecular weight of Cardiogen?

The unmodified free AEDR tetrapeptide has an approximate molecular weight of 489.48 g/mol.

Is Cardiogen the same as Vesugen?

No. Cardiogen is commonly identified as the AEDR tetrapeptide, while Vesugen is the KED tripeptide.

Does Cardiogen repair cardiac tissue?

Cardiac tissue repair has not been established as a clinically proven effect of Cardiogen.

What does Cardiogen 20mg mean?

The 20mg designation refers to the labelled quantity of research material, not a recommended human dose.

Is Cardiogen approved for medical use?

Cardiogen is not an established approved medicine for human cardiovascular treatment.

Cardiogen 20mg – Product Summary

Cardiogen 20mg is a synthetic tetrapeptide commonly identified by the AEDR sequence and associated with the Khavinson short peptide bioregulator research programme.

Its scientific background includes limited laboratory investigations involving myocardial tissue models and molecular interactions with cellular proteins.

Current evidence does not establish therapeutic effectiveness in humans, and Cardiogen should not be presented as a proven heart treatment.

Researchers should verify the exact amino acid sequence, molecular identity, purity, batch documentation and storage requirements before selecting Cardiogen 20mg for laboratory investigation.